In 2002, the National Rosacea Society assembled an expert committee to develop the first standard classification of rosacea. This original classification was intended to be updated as scientific knowledge and clinical experience increased. Over the last 15 years, significant new insights into rosacea's pathogenesis and pathophysiology have emerged, and the disorder is now widely addressed in clinical practice. Growing knowledge of rosacea's pathophysiology has established that a consistent multivariate disease process underlies the various clinical manifestations of this disorder, and the clinical significance of each of these elements is increasing as more is understood. This review proposes an updated standard classification of rosacea that is based on phenotypes linked to our increased understanding of disease pathophysiology. This updated classification is intended to provide clearer parameters to conduct investigations, guide diagnosis, and improve treatment. ( J Am Acad Dermatol 2018;78:148-55.) 
R osacea is well established as a chronic cutaneous syndrome, encompassing various combinations of potential signs and symptoms that manifest primarily on the convexities of the central face (cheeks, chin, nose, and central part of forehead) and are often characterized by repeated remissions and exacerbations. Rosacea is commonly diagnosed in certain demographic groups, and in epidemiologic studies of whites, its prevalence has been 10% or higher. [1] [2] [3] [4] Although it has been most frequently observed in patients with fair skin, rosacea has also been diagnosed in Asians, Latin Americans, African-Americans, and Africans ( Figs 1 to 4) . [5] [6] [7] [8] The disorder is identified more often in women than in men, and although it may occur at any age, the onset typically occurs at any time after age 30.
In 2002, the National Rosacea Society (NRS) assembled an expert committee to develop a classification system to provide standard criteria essential for performing research, analyzing results, and comparing data from different sources, as well as to serve as a diagnostic reference in clinical practice. 9 The classification system also established standard terminology to facilitate clear communication among a broad range of basic, clinical, and other researchers; practicing dermatologists; primary care physicians; ophthalmologists; other medical specialists; regulatory authorities; health and insurance administrators; patients; and the general public. Because the etiology and pathogenesis of rosacea were unknown at that time and there were no histologic or serologic markers for the disease, the system was based on morphologic characteristics alone to provide a framework that could be readily updated as new discoveries were made. The standard classification was proposed as a provisional system, and it was hoped that with increased scientific knowledge and experience in clinical practice, the definition of rosacea would ultimately be based on pathophysiology.
Over the 15 years since the classification's development, scientific investigations have yielded significant insight into rosacea's pathogenesis and pathophysiology, whereas clinical experience has suggested a need for an updated approach to diagnosis, classification, and treatment. 10, 11 To fulfill the directive of the original authors of the 2002 classification system, the NRS convened a committee to update the standard classification of rosacea, including new parameters for its diagnosis, assessment, and common presentations. The revised standard diagnostic features were adopted on the basis of their positive predictive value as supported by rosacea experts. 12 In addition, new scientific evidence has shown that rosacea's diverse features may be part of a continuum of inflammation that may not be clinically visible but is detectable histologically and biochemically. [13] [14] [15] [16] This suggests that the common presentations of flushing and fixed centrofacial erythema may progress to include papules and pustules and potentially lead (in a small proportion of cases) to subsequent development of phymas. 17, 18 This is further supported by the observation that in patients who have been treated successfully for their papules and pustules, the erythema and flushing often remain. 18 The following updates have been developed by the committee and reviewed by a panel of 21rosacea experts worldwide and are intended tobe useful to clinicians and researchers byproviding clearer and more meaningful parameters to conduct new investigations, as well as to build on existing findings while offering a more meaningful guide to diagnosis and treatment.
DIAGNOSTIC CRITERIA
The original standard classification of rosacea identified the most common patterns or groupings of signs and symptoms and designated them as follows: subtype 1, erythematotelangiectatic; subtype 2, papulopustular; subtype 3, phymatous; and subtype 4, ocular. Although didactically successful, the subtype designations were widely utilized individually and construed as distinct disorders, ignoring the frequent simultaneous occurrence of more than 1 subtype and the potential progression from one subtype to another. 18 Moreover, the focus on subtypes tended to limit consideration of the full range of potential signs and symptoms that may occur in individual patients and that, in some cases, may confound the assessment of severity.
Because rosacea can encompass a multitude of possible combinations of signs and symptoms, the following updated classification system is based on phenotypesdobservable characteristics that can result from genetic and/or environmental influencesdto provide the necessary means of assessing and treating rosacea in a manner that is consistent with each individual patient's experience (Table I ). The phenotypes and diagnostic criteria are largely in agreement with those recommended by the global rosacea consensus panel in 2016, and at least 1 diagnostic or 2 major phenotypes are required for the diagnosis of rosacea. 12 
Diagnostic phenotypes
A diagnosis of rosacea may be considered in the presence of 1 of the following diagnostic cutaneous signs. 12 
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Fixed centrofacial erythema in a characteristic pattern that may periodically intensify. Persistent redness of the facial skin is the most common sign of rosacea in Fitzpatrick phototypes I to IV; however, erythema may be difficult to detect in the darker phototypes (V and VI). In patients with type V or VI skin, papules and pustules may be the first clearly visible signs of rosacea. A personal history, drug history, and complete physical examination are helpful to clinicians in excluding other entities in the possible differential diagnoses such as lupus erythematosus, steroid-induced rosacea, or seborrheic eczema. 13 In rosacea, a history of flushing or blushing is common in phototypes I to IV.
Phymatous changes. These can include patulous follicles, skin thickening or fibrosis, glandular hyperplasia, and a bulbous appearance of the nose. Rhinophyma is the most common form, but other phymas may occur.
Major phenotypes
Major cutaneous signs often appear with 1 or more of the diagnostic features, although some can occur independently. Without a diagnostic phenotype, the presence of 2 or more major features may be considered diagnostic. 12 Major phenotypes include the following.
Papules and pustules. Dome-shaped red papules with or without accompanying pustules, often in crops and dominant in the centrofacial area, are typical. Nodules may also occur. Although patients with concomitant acne may exhibit comedones, comedones should be considered part of an acne process unrelated to rosacea, as has been supported by recent transcriptome analyses in acne and rosacea. 13, [19] [20] [21] Flushing. Frequent and typically prolonged flushing (sometimes blushing) is common except in darker skin tones, in which case flushing may be subjectively experienced without obvious erythema. In contrast to other erythematous changes, in rosacea flushing can occur within seconds to minutes in response to neurovascular stimulation by trigger factors. [13] [14] [15] 19, 22 Telangiectasia. Telangiectasias, which are common signs of rosacea and are predominantly centrofacial in phototypes I to IV, are rarely seen in the darker phototypes V and VI. Use of a dermatoscope may allow for detection of telangiectasias in patients with darker skin types.
Ocular manifestations. Ocular manifestations occur in many patients. These are outlined in detail in the following section. 
Secondary phenotypes
23 Pruritus (itch) is not a typical characteristic of rosacea but may also occur.
Edema. Facial edema may accompany or follow prolonged erythema or flushing as a result of postcapillary extravasation during inflammation. 24 Sometimes soft edema may last for days or be aggravated by inflammatory changes. Solid facial edema (persisting hard, nonpitting edema) can occur with rosacea, often as a sequela of papules and pustules, and also independently of redness, papules and pustules, or phymatous changes. Commonly, a combination of blood and lymphatic vessel edema occurs, although the dominance may vary. 13 Dry appearance. Central facial skin may be rough and scaly so as to resemble dry skin and suggest an eczematous dermatitis, and rosacea may often include the coexistence of seborrheic dermatitis. This ''dry appearance'' may be associated with burning or stinging sensations and may be caused by irritation rather than the disease process.
Ocular rosacea
Ocular rosacea can occur in the context of mild, moderate, or severe dermatologic disease and may also appear in the absence of diagnostic skin manifestations (Fig 5) . Ocular signs strongly suggestive of ocular rosacea include (1) lid margin telangiectases, (2) interpalpebral conjunctival injection, (3) spade-shaped infiltrates in the cornea, and (4) scleritis and sclerokeratitis.
Common symptoms that may suggest ocular rosacea but are not specific to the disorder include (1) burning, (2) stinging, (3) light sensitivity, and (4) foreign object sensation.
Ocular signs that commonly appear in rosacea but are not specific to the disorder include (1) Meibomian gland dysfunction (''posterior'' blepharitis) characterized by inspissation and inflammation of the Meibomian glands (chalazia); (2) conjunctivitis; and (3) ''honey crust'' and cylindrical collarette accumulation at the base of the lashes, 25 irregularity of the lid margin architecture, and evaporative tear dysfunction (rapid tear breakup time).
The external ocular signs that will be readily seen by the dermatologist include (1) lid margin telangiectases, (2) characteristic interpalpebral conjunctival telangiectases, (3) inspissation of the Meibomian glands, and (4) chalazia.
The ocular signs that will likely require slit-lamp examination by the ophthalmologist include (1) keratitis, including a range of disease severity from epithelial defects to corneal infiltrates and thinning; (2) corneal spade-shaped infiltrates and vascularization; and (3) scleritis.
Disease severity can be categorized as follows: (1) mild (blepharitis), (2) mild to moderate (blepharitis plus conjunctival injection [indicating more diffuse ocular surface dysfunction]), (3) moderate to severe (involvement of the cornea with punctate keratitis, infiltrates, and vascularization), and (4) severe (scleritis or keratitis).
OTHER CONSIDERATIONS Major presentations
Although the new classification's common patterns or groupings of signs and symptoms are not to be considered subtypes or units for research or individual diagnosis and treatment, they may now be referenced in updated terms that reflect current knowledge of their pathophysiology, including neurovascular, inflammatory, phymatous, and ocular. For example, it is proposed that the original erythematotelangiectatic subtype be considered a primary neurovascular inflammatory response (neurovascular inflammation), whereas the papulopustular subtype would encompass both neurovascular and enhanced innate and adaptive immune systemeassociated inflammatory responses. Of note, both are inflammatory mechanisms that lead to different signs.
Progression
Although rosacea's various phenotypes may appear in different combinations and at different times, research suggests that all may be manifestations of the same underlying inflammatory continuum [13] [14] [15] [16] and that rosacea may progress not only in severity but to include additional phenotypes. 17, 18 Recent studies point to a multivariate set of pathogenic pathways, including defects in the innate and adaptive immune systems, J AM ACAD DERMATOL VOLUME 78, NUMBER 1 mast cells and related biochemical mechanisms, and the neurovascular system. [13] [14] [15] [16] [26] [27] [28] It now appears likely that initial erythema and vascular manifestations such as telangiectasia may be in a continuum initiated by a combination of neurovascular dysregulation and innate immune responses, including increased LL37 and serine proteases. 13, 20, 22, 26, 29, 30 Papules are characterized by increased Th1 and Th17 cells, as well as by plasma cells, mast cells, and macrophages, 22, 26 whereas pustules are characterized by increased production of neutrophil-recruiting chemokines. 22 Although the immune response gene expression levels peak in rosacea with papules and pustules, a marked infiltrate and upregulation of genes involved in innate and adaptive immune responses are also present in neurovascular and phymatous presentations of rosacea, suggesting a continuum of inflammation through different molecular pathways and cell activities that are reflected in the different clinical signs and symptoms. Moreover, studies indicate a marked upregulation of mast cell density as a common factor in all major presentations, but the greatest increase occurs in rosacea characterized by papules and pustules, demonstrating a link between the neurovascular, inflammatory, phymatous, and ocular presentations. 13, 26, 27 Because various inflammatory pathways appear to be more operative in some individual presentations than in others, more epidemiological studies are needed to clarify this clinical impression. For example, although phymatous changes (a diagnostic feature of rosacea) may appear without erythema in some patients, biopsies reveal an inflammatory infiltrate and transcriptome analysis demonstrates the presence of inflammatory mediators, suggesting that subclinical inflammation is present. [20] [21] [22] Consequently, a current working hypothesis is that early phymatous rosacea without a clear history and clinical presentation of erythema may be associated with subclinical neuroinflammation and adaptive or innate immune responses that then progress to fibrosis and glandular hyperplasia. This is supported by the fact that all patients with phymatous rosacea in the transcriptome analysis showed increased expression levels of genes associated with inflammation and immune responses. 13, 15, 20, 22 Thus, although phymatous changes may not occur in all patients, subclinical fibrotic changes may have already occurred on the molecular level before they become clinically evident in neurovascular and inflammatory rosacea, leading to the conclusion that fibrosis in rosacea may start much earlier than might be expected through clinical observation. 13 
Severity
Various instruments (Table II) have been used to assess each of the standard phenotypes as well as for global assessment of rosacea. Examples of tools in existence for the various phenotypes include the for persistent erythema, lesion counts and an investigator's global assessment 35 for papules and pustules, and the Rosacea Quality of Life Index (RosaQoL) 36 for psychosocial effects. In 2004, the NRS expert committee published a standard grading system for rosacea in which primary and secondary features of rosacea are graded as absent, mild, moderate, or severe and that also provides for a global assessment on the same scale. 37 There is a need for a single updated scale that includes standardized severity assessments of the diagnostic, major, and secondary phenotypes of rosacea and can be used for all phototypes.
Psychosocial effects
A multitude of surveys over the last 15 years have documented rosacea's adverse impact on emotional, social, and occupational well-being, including its link to severity. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] The psychologic burden alone includes depression, anxiety, and worry, and appropriate severity scales to measure this dimension include the RosaQoL, the Dermatology Quality of Life Index, 49 the Depression Anxiety Stress Scale, 50 and the Penn State Worry Questionnaire, 51 among others. With the exception of the RosaQoL, which excludes phymatous changes and establishes no minimal important difference, the scales are nonspecific for rosacea, and further research may be needed to adequately measure its distinct dimensions, as well as to precisely measure the impact of rosacea on social and occupational interactions of disparate ethnic groups.
CONCLUSION
This updated classification of rosacea is intended to provide accuracy and flexibility appropriate for the study, diagnosis, evaluation, and treatment of rosacea within the context of current scientific understanding and clinical experience. Growing knowledge of rosacea's pathophysiology has increasingly found that a consistent multivariate disease process appears to underlie the various potential manifestations of the disorder, and its clinical significance may increase substantially as more is understood about the many comorbidities reported in recent studies. As with the original classification of rosacea, this updated standard system is considered provisional and may require modification as the etiology and pathogenesis of rosacea become clearer and its relevance and applicability are tested by investigators and clinicians. The authors welcome reports on the usefulness and limitations of these criteria. 
